[ Back to EurekAlert! ]

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute

Pasi Janne, M.D., Ph.D., Dana-Farber Cancer Institute

Caption: Pasi Janne, M.D., Ph.D., and colleagues are reporting in the New England Journal of Medicine that non-small cell lung cancer patients whose tumor cells had an abnormal ALK gene fared better if treated with crizotinib, a targeted therapy, than with traditional chemotherapy.

Credit: Sam Ogden

Usage Restrictions: None

Related news release: Targeted therapy boosts lung cancer outcomes


[ Back to EurekAlert! ]